The pharmacokinetic considerations and adverse effects of DPP-4 inhibitors [corrected]. (Q38205588)

31 August 2017

title

The pharmacokinetic considerations and adverse effects of DPP-4 inhibitors [corrected]. (English)

1 reference

31 August 2017

1 reference

Theodosios D. Filippatos

series ordinal

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24746233%20AND%20SRC:MED&resulttype=core&format=json

31 May 2020

Moses Elisaf

series ordinal

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24746233%20AND%20SRC:MED&resulttype=core&format=json

31 May 2020

2

Vasilios G Athyros

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24746233%20AND%20SRC:MED&resulttype=core&format=json

31 May 2020

language of work or name

English

0 references

publication date

19 April 2014

1 reference

Expert Opinion on Drug Metabolism & Toxicology

31 August 2017

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24746233%20AND%20SRC:MED&resulttype=core&format=json

31 May 2020

volume

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24746233%20AND%20SRC:MED&resulttype=core&format=json

31 May 2020

issue

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24746233%20AND%20SRC:MED&resulttype=core&format=json

31 May 2020

page(s)

787-812

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24746233%20AND%20SRC:MED&resulttype=core&format=json

Standards of medical care in diabetes--2014

31 May 2020

cites work

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2014.907274

Differences in metabolic parameters and cardiovascular risk between American Diabetes Association and World Health Organization definition of impaired fasting glucose in European Caucasian subjects: a cross-sectional study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2014.907274

Small high-density lipoprotein (HDL) subclasses are increased with decreased activity of HDL-associated phospholipase A₂ in subjects with prediabetes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2014.907274

Does combination therapy with statins and fibrates prevent cardiovascular disease in diabetic patients with atherogenic mixed dyslipidemia?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2014.907274

Combination drug treatment in obese diabetic patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2014.907274

Combination of fenofibrate with non-statin drug regimens.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2014.907274

Fenofibrate plus simvastatin (fixed-dose combination) for the treatment of dyslipidaemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2014.907274

Effect of orlistat, micronised fenofibrate and their combination on metabolic parameters in overweight and obese patients with the metabolic syndrome: the FenOrli study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2014.907274

A review of time courses and predictors of lipid changes with fenofibric acid-statin combination

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2014.907274

The place of GLP-1-based therapy in diabetes management: differences between DPP-4 inhibitors and GLP-1 receptor agonists

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2014.907274

DPP-4 inhibitors: impact on glycemic control and cardiovascular risk factors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2014.907274

Cardiovascular effects of the DPP-4 inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2014.907274

Inhibitor selectivity in the clinical application of dipeptidyl peptidase-4 inhibition

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2014.907274

The dipeptidyl peptidase IV family in cancer and cell biology.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2014.907274

Genetic ablation or pharmacological blockade of dipeptidyl peptidase IV does not impact T cell-dependent immune responses

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2014.907274

Sequence, purification, and cloning of an intracellular serine protease, quiescent cell proline dipeptidase

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2014.907274

Cloning, expression and chromosomal localization of a novel human dipeptidyl peptidase (DPP) IV homolog, DPP8

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2014.907274

Dipeptidyl peptidase 9 has two forms, a broad tissue distribution, cytoplasmic localization and DPIV-like peptidase activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2014.907274

Dipeptidyl peptidase IV inhibition for the treatment of type 2 diabetes: potential importance of selectivity over dipeptidyl peptidases 8 and 9.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2014.907274

Adverse effects of dipeptidyl peptidases 8 and 9 inhibition in rodents revisited

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2014.907274

Biochemistry, pharmacokinetics, and toxicology of a potent and selective DPP8/9 inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2014.907274

Recent advances in non-peptidomimetic dipeptidyl peptidase 4 inhibitors: medicinal chemistry and preclinical aspects

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2014.907274

Metabolism and excretion of the dipeptidyl peptidase 4 inhibitor [14C]sitagliptin in humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2014.907274

Effect of renal insufficiency on the pharmacokinetics of sitagliptin, a dipeptidyl peptidase-4 inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2014.907274

Absorption, metabolism, and excretion of [14C]vildagliptin, a novel dipeptidyl peptidase 4 inhibitor, in humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2014.907274

Discovery and preclinical profile of Saxagliptin (BMS-477118): a highly potent, long-acting, orally active dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2014.907274

Potency, selectivity and prolonged binding of saxagliptin to DPP4: maintenance of DPP4 inhibition by saxagliptin in vitro and ex vivo when compared to a rapidly-dissociating DPP4 inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2014.907274

Pharmacokinetics of the dipeptidyl peptidase 4 inhibitor saxagliptin in rats, dogs, and monkeys and clinical projections

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2014.907274

The metabolism and disposition of the oral dipeptidyl peptidase-4 inhibitor, linagliptin, in humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2014.907274

Pharmacokinetics of linagliptin in subjects with hepatic impairment

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2014.907274

Pharmacokinetics and metabolism of [14C]anagliptin, a novel dipeptidyl peptidase-4 inhibitor, in humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2014.907274

Metabolism and disposition of the dipeptidyl peptidase IV inhibitor teneligliptin in humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2014.907274

Gemigliptin, a novel dipeptidyl peptidase 4 inhibitor: first new anti-diabetic drug in the history of Korean pharmaceutical industry

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2014.907274

Efficacy and safety of sitagliptin monotherapy in Japanese patients with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2014.907274

Effect of initial combination therapy with sitagliptin, a dipeptidyl peptidase-4 inhibitor, and metformin on glycemic control in patients with type 2 diabetes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2014.907274

Elevated hepatic enzymes potentially associated with sitagliptin

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2014.907274

Probable linagliptin-induced liver toxicity: a case report

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2014.907274

An assessment of adverse effects of vildagliptin versus comparators on the liver, the pancreas, the immune system, the skin and in patients with impaired renal function from a large pooled database of Phase II and III clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2014.907274

One year of sitagliptin treatment protects against islet amyloid-associated β-cell loss and does not induce pancreatitis or pancreatic neoplasia in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2014.907274

The DPP-4 inhibitor linagliptin restores β-cell function and survival in human isolated islets through GLP-1 stabilization

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2014.907274

Reduction of both beta cell death and alpha cell proliferation by dipeptidyl peptidase-4 inhibition in a streptozotocin-induced model of diabetes in mice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2014.907274

Pancreatitis with pancreatic tail swelling associated with incretin-based therapies detected radiologically in two cases of diabetic patients with end-stage renal disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2014.907274

A case of severe acute necrotizing pancreatitis after administration of sitagliptin

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2014.907274

A rare case of autoimmune polyglandular syndrome type IIIc

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2014.907274

Glucagonlike peptide 1-based therapies and risk of hospitalization for acute pancreatitis in type 2 diabetes mellitus: a population-based matched case-control study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2014.907274

Acute pancreatitis in type 2 diabetes treated with exenatide or sitagliptin: a retrospective observational pharmacy claims analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2014.907274

Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2014.907274

Alogliptin after acute coronary syndrome in patients with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2014.907274

Dipeptidyl peptidase-4 inhibitors and pancreatitis risk: a meta-analysis of randomized clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2014.907274

Gliptins (dipeptidyl peptidase-4 inhibitors) and risk of acute pancreatitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2014.907274

Saxagliptin added to a thiazolidinedione improves glycemic control in patients with type 2 diabetes and inadequate control on thiazolidinedione alone

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2014.907274

Obesity and arterial compliance alterations

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2014.907274

Dipeptidyl peptidase-4 inhibitors attenuate endothelial function as evaluated by flow-mediated vasodilatation in type 2 diabetic patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2014.907274

A thorough QTc study to assess the effect of sitagliptin, a DPP4 inhibitor, on ventricular repolarization in healthy subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2014.907274

Teneligliptin: a DPP-4 inhibitor for the treatment of type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2014.907274

Sitagliptin-associated drug allergy: review of spontaneous adverse event reports

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2014.907274

The development of angioedema in a patient with type 2 diabetes due to a novel dipeptidyl peptidase-IV inhibitor, anagliptin

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2014.907274

Sitagliptin-associated angioedema

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2014.907274

Dipeptidyl peptidase IV in angiotensin-converting enzyme inhibitor associated angioedema

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2014.907274

Angio-oedema induced by dual dipeptidyl peptidase inhibitor and angiotensin II receptor blocker: a first case report

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2014.907274

Dipeptidyl peptidase-IV inhibitor use associated with increased risk of ACE inhibitor-associated angioedema

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2014.907274

Safety and tolerability of sitagliptin in clinical studies: a pooled analysis of data from 10,246 patients with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2014.907274

Dipeptidyl peptidase-4 inhibitors and angioedema: a class effect?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2014.907274

Psoriasiform eruption triggered by a dipeptidyl peptidase IV inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2014.907274

Saxagliptin: a clinical review in the treatment of type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2014.907274

Drug-induced bullous pemphigoid in diabetes mellitus patients receiving dipeptidyl peptidase-IV inhibitors plus metformin.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2014.907274

Clinically relevant reductions in HbA1c without hypoglycaemia: results across four studies of saxagliptin

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2014.907274

Efficacy and safety of sitagliptin when added to ongoing metformin therapy in patients with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2014.907274

Suicide attempt by an overdose of sitagliptin, an oral hypoglycemic agent: a case report and a review of the literature

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2014.907274

Saxagliptin added to a submaximal dose of sulphonylurea improves glycaemic control compared with uptitration of sulphonylurea in patients with type 2 diabetes: a randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2014.907274

Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, in patients with type 2 diabetes mellitus inadequately controlled on glimepiride alone or on glimepiride and metformin.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2014.907274

Alogliptin added to insulin therapy in patients with type 2 diabetes reduces HbA(1C) without causing weight gain or increased hypoglycaemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2014.907274

Renal failure and rhabdomyolysis associated with sitagliptin and simvastatin use.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2014.907274

Rhabdomyolysis caused by a potential sitagliptin-lovastatin interaction

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2014.907274

Statin-associated adverse effects beyond muscle and liver toxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2014.907274

The effect of dipeptidyl peptidase-IV inhibition on bone in a mouse model of type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2014.907274

Behavioral characterization of CD26 deficient mice in animal tests of anxiety and antidepressant-like activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2014.907274

Deficiency of CD26 results in a change of cytokine and immunoglobulin secretion after stimulation by pokeweed mitogen.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2014.907274

Dipeptidyl peptidase IV inhibition with MK0431 improves islet graft survival in diabetic NOD mice partially via T-cell modulation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2014.907274

Glucose-lowering activity of the dipeptidyl peptidase-4 inhibitor saxagliptin in drug-naive patients with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2014.907274

Dipeptidyl peptidase IV inhibition does not adversely affect immune or virological status in HIV infected men and women: a pilot safety study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2014.907274

Incretin-based therapies--review of the physiology, pharmacology and emerging clinical experience.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2014.907274

Dipeptidyl peptidase IV and related enzymes in cell biology and liver disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2014.907274

Efficacy and safety of incretin therapy in type 2 diabetes: systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2014.907274

Safety and tolerability of linagliptin: a pooled analysis of data from randomized controlled trials in 3572 patients with type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2014.907274

The efficacy and safety of vildagliptin in patients with type 2 diabetes: a meta-analysis of randomized clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2014.907274

Dipeptidyl peptidase inhibitors, an emerging drug class for inflammatory disease?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2014.907274

Efficacy and tolerability of the DPP-4 inhibitor alogliptin combined with pioglitazone, in metformin-treated patients with type 2 diabetes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2014.907274

Efficacy and safety of adding the dipeptidyl peptidase-4 inhibitor alogliptin to metformin therapy in patients with type 2 diabetes inadequately controlled with metformin monotherapy: a multicentre, randomised, double-blind, placebo-controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2014.907274

Effect of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy on glycemic control in patients with type 2 diabetes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2014.907274

Exenatide and sitagliptin are not associated with increased risk of acute renal failure: a retrospective claims analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2014.907274

Beneficial endocrine but adverse exocrine effects of sitagliptin in the human islet amyloid polypeptide transgenic rat model of type 2 diabetes: interactions with metformin

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2014.907274

Glucagon-like peptide-1 and exendin-4 stimulate beta-cell neogenesis in streptozotocin-treated newborn rats resulting in persistently improved glucose homeostasis at adult age.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2014.907274

Exendin-4 stimulates both beta-cell replication and neogenesis, resulting in increased beta-cell mass and improved glucose tolerance in diabetic rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2014.907274

Chronic GLP-1 receptor activation by exendin-4 induces expansion of pancreatic duct glands in rats and accelerates formation of dysplastic lesions and chronic pancreatitis in the Kras(G12D) mouse model

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2014.907274

Marked expansion of exocrine and endocrine pancreas with incretin therapy in humans with increased exocrine pancreas dysplasia and the potential for glucagon-producing neuroendocrine tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2014.907274

Pancreatitis, pancreatic, and thyroid cancer with glucagon-like peptide-1-based therapies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2014.907274

A critical analysis of the clinical use of incretin-based therapies: Are the GLP-1 therapies safe?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2014.907274

A critical analysis of the clinical use of incretin-based therapies: The benefits by far outweigh the potential risks

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2014.907274

Safety of dipeptidyl peptidase-4 inhibitors: a meta-analysis of randomized clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2014.907274

Do antidiabetic medications play a specific role in differentiated thyroid cancer compared to other cancer types?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2014.907274

Transport of the dipeptidyl peptidase-4 inhibitor sitagliptin by human organic anion transporter 3, organic anion transporting polypeptide 4C1, and multidrug resistance P-glycoprotein.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2014.907274

Effect of sitagliptin on the pharmacokinetics of simvastatin

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2014.907274

Sitagliptin, an dipeptidyl peptidase-4 inhibitor, does not alter the pharmacokinetics of the sulphonylurea, glyburide, in healthy subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2014.907274

Pharmacokinetic evaluation of atorvastatin and sitagliptin in combination for the treatment of type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2014.907274

Effect of ABCB1 polymorphisms and atorvastatin on sitagliptin pharmacokinetics in healthy volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2014.907274

Dipeptidylpeptidase-4 inhibitors (gliptins): focus on drug-drug interactions

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2014.907274

Vildagliptin, a novel dipeptidyl peptidase IV inhibitor, has no pharmacokinetic interactions with the antihypertensive agents amlodipine, valsartan, and ramipril in healthy subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2014.907274

Evaluation of the potential for steady-state pharmacokinetic interaction between vildagliptin and simvastatin in healthy subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2014.907274

Effect of the novel oral dipeptidyl peptidase IV inhibitor vildagliptin on the pharmacokinetics and pharmacodynamics of warfarin in healthy subjects.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2014.907274

Characterization of the in vitro and in vivo metabolism and disposition and cytochrome P450 inhibition/induction profile of saxagliptin in human

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2014.907274

Effect of rifampicin on the pharmacokinetics and pharmacodynamics of saxagliptin, a dipeptidyl peptidase-4 inhibitor, in healthy subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2014.907274

Pharmacokinetics of alogliptin when administered with food, metformin, or cimetidine: a two-phase, crossover study in healthy subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2014.907274

Coadministration of pioglitazone or glyburide and alogliptin: pharmacokinetic drug interaction assessment in healthy participants.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2014.907274

Postmenopausal hormone therapy for disease prevention: have we learned any lessons from the past?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2014.907274

Evaluation and prediction of potential drug-drug interactions of linagliptin using in vitro cell culture methods

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2014.907274

Concentration-dependent plasma protein binding of the novel dipeptidyl peptidase 4 inhibitor BI 1356 due to saturable binding to its target in plasma of mice, rats and humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2014.907274

Clinical pharmacokinetics and pharmacodynamics of linagliptin.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2014.907274

Linagliptin: a review of its use in the management of type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2014.907274

Linagliptin-a novel dipeptidyl peptidase inhibitor for type 2 diabetes therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2014.907274

Evaluation of the potential for steady-state pharmacokinetic and pharmacodynamic interactions between the DPP-4 inhibitor linagliptin and metformin in healthy subjects.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2014.907274

Renal failure and rhabdomyolysis associated with sitagliptin and simvastatin use. But what about the amiodarone?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2014.907274

Linagliptin, a dipeptidyl peptidase-4 inhibitor with a unique pharmacological profile, and efficacy in a broad range of patients with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2014.907274

Effects of ketoconazole and rifampicin on the pharmacokinetics of gemigliptin, a dipeptidyl peptidase-IV inhibitor: a crossover drug-drug interaction study in healthy male Korean volunteers.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2014.907274

Evaluation of the pharmacokinetic interaction between the dipeptidyl peptidase IV inhibitor LC15-0444 and pioglitazone in healthy volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2014.907274

Efficacy and safety of saxagliptin in combination with metformin compared with sitagliptin in combination with metformin in adult patients with type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2014.907274

Efficacy and safety of the dipeptidyl peptidase-4 inhibitor gemigliptin compared with sitagliptin added to ongoing metformin therapy in patients with type 2 diabetes inadequately controlled with metformin alone.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2014.907274

(2R)-4-oxo-4-[3-(trifluoromethyl)-5,6-dihydro[1,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl]-1-(2,4,5-trifluorophenyl)butan-2-amine: a potent, orally active dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2014.907274

Pharmacokinetics and pharmacodynamic effects of the oral DPP-4 inhibitor sitagliptin in middle-aged obese subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2014.907274

Pharmacokinetic and pharmacodynamic properties of multiple oral doses of sitagliptin, a dipeptidyl peptidase-IV inhibitor: a double-blind, randomized, placebo-controlled study in healthy male volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2014.907274

1-[[(3-hydroxy-1-adamantyl)amino]acetyl]-2-cyano-(S)-pyrrolidine: a potent, selective, and orally bioavailable dipeptidyl peptidase IV inhibitor with antihyperglycemic properties

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2014.907274

Clinical pharmacokinetics and pharmacodynamics of vildagliptin

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2014.907274

Pharmacokinetic study of saxagliptin in healthy Chinese subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2014.907274

Discovery of alogliptin: a potent, selective, bioavailable, and efficacious inhibitor of dipeptidyl peptidase IV

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2014.907274

Pharmacokinetic, pharmacodynamic, and efficacy profiles of alogliptin, a novel inhibitor of dipeptidyl peptidase-4, in rats, dogs, and monkeys

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2014.907274

Pharmacokinetic, pharmacodynamic, and tolerability profiles of the dipeptidyl peptidase-4 inhibitor alogliptin: a randomized, double-blind, placebo-controlled, multiple-dose study in adult patients with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2014.907274

Pharmacokinetics, pharmacodynamics, and tolerability of single increasing doses of the dipeptidyl peptidase-4 inhibitor alogliptin in healthy male subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2014.907274

Dipeptidyl peptidase-4 inhibitors in the treatment of type 2 diabetes: a comparative review

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2014.907274

(R)-8-(3-amino-piperidin-1-yl)-7-but-2-ynyl-3-methyl-1-(4-methyl-quinazolin-2-ylmethyl)-3,7-dihydro-purine-2,6-dione (BI 1356), a novel xanthine-based dipeptidyl peptidase 4 inhibitor, has a superior potency and longer duration of action compared wi

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2014.907274

Pharmacokinetic, pharmacodynamic, and tolerability profiles of the dipeptidyl peptidase-4 inhibitor linagliptin: a 4-week multicenter, randomized, double-blind, placebo-controlled phase IIa study in Japanese type 2 diabetes patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2014.907274

Linagliptin, a dipeptidyl peptidase-4 inhibitor in development for the treatment of type 2 diabetes mellitus: a Phase I, randomized, double-blind, placebo-controlled trial of single and multiple escalating doses in healthy adult male Japanese subjec

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2014.907274

Pharmacokinetics, pharmacodynamics and tolerability of multiple oral doses of linagliptin, a dipeptidyl peptidase-4 inhibitor in male type 2 diabetes patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2014.907274

Safety, tolerability, pharmacokinetics, and pharmacodynamics of single oral doses of BI 1356, an inhibitor of dipeptidyl peptidase 4, in healthy male volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2014.907274

A comparative study of the binding modes of recently launched dipeptidyl peptidase IV inhibitors in the active site

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2014.907274

A novel, potent, and long-lasting dipeptidyl peptidase-4 inhibitor, teneligliptin, improves postprandial hyperglycemia and dyslipidemia after single and repeated administrations.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2014.907274

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2014.907274

Pharmacokinetics of Teneligliptin in Subjects With Renal Impairment

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2014.907274

Pharmacokinetics and pharmacodynamics of LC15-0444, a novel dipeptidyl peptidase IV inhibitor, after multiple dosing in healthy volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2014.907274

Pharmacokinetics, pharmacodynamics, and tolerability of the dipeptidyl peptidase IV inhibitor LC15-0444 in healthy Korean men: a dose-block-randomized, double-blind, placebo-controlled, ascending single-dose, Phase I study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2014.907274

Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing metformin therapy in patients with type 2 diabetes inadequately controlled with metformin alone.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2014.907274

Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing pioglitazone therapy in patients with type 2 diabetes: a 24-week, multicenter, randomized, double-blind, placebo-controlled, parallel-group study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2014.907274

Efficacy and safety of sitagliptin added to ongoing metformin and pioglitazone combination therapy in a randomized, placebo-controlled, 26-week trial in patients with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2014.907274

Efficacy and safety of sitagliptin when added to insulin therapy in patients with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2014.907274

Efficacy and tolerability of vildagliptin in drug-naïve patients with type 2 diabetes and mild hyperglycaemia*.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2014.907274

Efficacy and tolerability of vildagliptin as an add-on to glimepiride in Japanese patients with Type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2014.907274

Effects of vildagliptin on glucose control in patients with type 2 diabetes inadequately controlled with a sulphonylurea

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2014.907274

Efficacy and safety of saxagliptin in drug-naïve Asian patients with type 2 diabetes mellitus: a randomized controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2014.907274

The efficacy and safety of saxagliptin when added to metformin therapy in patients with inadequately controlled type 2 diabetes with metformin alone

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2014.907274

Efficacy and safety of alogliptin added to metformin in Japanese patients with type 2 diabetes: a randomized, double-blind, placebo-controlled trial with an open-label, long-term extension study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2014.907274

Efficacy and safety of the dipeptidyl peptidase-4 inhibitor alogliptin in patients with type 2 diabetes inadequately controlled by glyburide monotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2014.907274

The role of GLP-1 mimetics and basal insulin analogues in type 2 diabetes mellitus: guidance from studies of liraglutide

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2014.907274

Linagliptin for patients aged 70 years or older with type 2 diabetes inadequately controlled with common antidiabetes treatments: a randomised, double-blind, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2014.907274

Efficacy, safety and dose-response relationship of teneligliptin, a dipeptidyl peptidase-4 inhibitor, in Japanese patients with type 2 diabetes mellitus.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2014.907274

A multicentre, multinational, randomized, placebo-controlled, double-blind, phase 3 trial to evaluate the efficacy and safety of gemigliptin (LC15-0444) in patients with type 2 diabetes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2014.907274

Multiple doses of sitagliptin, a selective DPP-4 inhibitor, do not meaningfully alter pharmacokinetics and pharmacodynamics of warfarin

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2014.907274

Sitagliptin, a dipeptidyl peptidase-4 inhibitor, does not affect the pharmacokinetics of ethinyl estradiol or norethindrone in healthy female subjects.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2014.907274

A randomized, open-label, crossover study to evaluate the pharmacokinetics of empagliflozin and linagliptin after coadministration in healthy male volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2014.907274

Effect of multiple oral doses of linagliptin on the steady-state pharmacokinetics of a combination oral contraceptive in healthy female adults: an open-label, two-period, fixed-sequence, multiple-dose study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2014.907274

Discovery and pharmacological characterization of N-[2-({2-[(2S)-2-cyanopyrrolidin-1-yl]-2-oxoethyl}amino)-2-methylpropyl]-2-methylpyrazolo[1,5-a]pyrimidine-6-carboxamide hydrochloride (anagliptin hydrochloride salt) as a potent and selective DPP-IV

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2014.907274

Glucagon-like peptide-1 (GLP-1) receptor agonism or DPP-4 inhibition does not accelerate neoplasia in carcinogen treated mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2014.907274

Dipeptidyl peptidase 8/9-like activity in human leukocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2014.907274

10.1517/17425255.2014.907274

21 January 2018

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24746233%20AND%20SRC:MED&resulttype=core&format=json

31 May 2020

1 reference